Tech Company Financing Transactions
Promentis Pharmaceuticals Funding Round
Promentis Pharmaceuticals, based in Milwaukee, secured $26 million from OrbiMed, Aisling Capital and F-Prime Capital.
Transaction Overview
Company Name
Announced On
3/31/2017
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Series C
Investors
OrbiMed (Lead Investor) (Klaus Veitinger)
Aisling Capital (Stacey Seltzer)
F-Prime Capital (Thomas Beck)
Proceeds Purpose
This financing will enable Promentis to advance its lead compound SXC-2023 through Phase 2 clinical proof of concept.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
826 N. Plankinton Ave. 400
Milwaukee, WI 53203
USA
Milwaukee, WI 53203
USA
Phone
Undisclosed
Website
Email Address
Overview
Promentis Pharmaceuticals, Inc. is a pharmaceutical company developing novel compounds for the treatment of schizophrenia and other central nervous system disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Klaus Veitinger
President
Daniel Lawton
VP - Finance
Stacy Holland
VP - R & D
Chad Beyer
VP - R & D
Michael Neary
Browse more venture capital transactions:
Prev: 3/31/2017: Phenom People venture capital transaction
Next: 3/31/2017: Magnolia Medical Technologies venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs